New minimally invasive treatment helps Upstate patients with peripheral artery disease
This approach is effective for patients with long lesions, who have already undergone failed endovascular procedures, or who may be suboptimal candidates for open surgical bypass. (Source: SUNY Upstate Medical)
Source: SUNY Upstate Medical - November 9, 2023 Category: Universities & Medical Training Tags: News Source Type: news

Evident Vascular secures $35M to develop IVUS platform
San Jose, CA-based startup Evident Vascular has secured $35 million in Series A funding from Vensana Capital to develop an AI-enabled intravascular ultrasound (IVUS) platform. The platform's development will focus on applications for the treatment of peripheral vascular disease, a slow and progressive circulation disorder that affects the legs and feet."Robust clinical trial data supporting utilization in both coronary and peripheral interventions are fueling future market growth," the company said. (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 18, 2023 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news

Home-Based Exercise Benefits Patients With PAD Home-Based Exercise Benefits Patients With PAD
New evidence shows home-based exercise could be a first-line therapy for walking limitations in peripheral artery disease.Medscape Medical News (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - October 6, 2023 Category: Orthopaedics Tags: Cardiology News Source Type: news

Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease
Zilebesiran met primary endpoint demonstrating greater than 15 mmHg reduction of systolic blood pressure at three months of treatment compared to placeboStudy met key secondary endpoints showing consistent and sustained reductions of systolic blood pressure at six monthsZilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertensionFull study results to be presented at an upcoming scientific conferenceBasel, 7 September 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam announced today that the Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi the...
Source: Roche Media News - September 7, 2023 Category: Pharmaceuticals Source Type: news

Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease
Zilebesiran met primary endpoint demonstrating greater than 15 mmHg reduction of systolic blood pressure at three months of treatment compared to placeboStudy met key secondary endpoints showing consistent and sustained reductions of systolic blood pressure at six monthsZilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertensionFull study results to be presented at an upcoming scientific conferenceBasel, 7 September 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam announced today that the Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi the...
Source: Roche Investor Update - September 7, 2023 Category: Pharmaceuticals Source Type: news

Who Is to Blame for the Rampant Overtreatment of Peripheral Artery Disease?
(MedPage Today) -- The recent New York Times article highlighting inappropriate treatment patterns among patients with peripheral artery disease (PAD) has made a serious but much needed impact on patients and physicians alike. The article is complemented... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 13, 2023 Category: Cardiology Source Type: news

PAD Procedure Overuse: Field in Peril or'A Few Bad Apples'? PAD Procedure Overuse: Field in Peril or'A Few Bad Apples'?
Two investigative stories highlighted peripheral artery disease treatment that left many patients with an amputation, the outcome they were told they could avoid.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 28, 2023 Category: Cardiology Tags: Cardiology News Source Type: news

Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk
Partnership combines Roche ’s proven track record of successfully developing and launching innovative medicines worldwide withAlnylam ’s leadership in RNAi therapeuticsZilebesiran, a Phase 2 RNAi therapeutic, has best-in-disease potential for patients with hypertension at high risk of cardiovascular morbidity and mortality, by robustly and durably lowering blood pressureHypertension, the leading cause of cardiovascular disease, affects more than 1.2 billion adults worldwide. While several therapies exist, a significant unmet need, especially for high risk patients, remains.1Basel, 24 July 2023 - Roche (SIX: RO, ROG; OT...
Source: Roche Media News - July 24, 2023 Category: Pharmaceuticals Source Type: news

Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk
Partnership combines Roche ’s proven track record of successfully developing and launching innovative medicines worldwide withAlnylam ’s leadership in RNAi therapeuticsZilebesiran, a Phase 2 RNAi therapeutic, has best-in-disease potential for patients with hypertension at high risk of cardiovascular morbidity and mortality, by robustly and durably lowering blood pressureHypertension, the leading cause of cardiovascular disease, affects more than 1.2 billion adults worldwide. While several therapies exist, a significant unmet need, especially for high risk patients, remains.1Basel, 24 July 2023 - Roche (SIX: RO, ROG; OT...
Source: Roche Investor Update - July 24, 2023 Category: Pharmaceuticals Source Type: news

Black Patients With Peripheral Artery Disease Have Worse Outcomes
TUESDAY, July 18, 2023 -- There are significant racial disparities in the diagnosis, treatment, and outcomes of peripheral artery disease (PAD), according to a study recently published in Advances in Therapy. Keith C. Ferdinand, M.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 18, 2023 Category: Pharmaceuticals Source Type: news

Profiting From Risky Atherectomies That Can Lead to Amputations
Medical device makers have bankrolled a cottage industry of doctors and clinics that perform artery-clearing procedures that can lead to amputations. (Source: NYT Health)
Source: NYT Health - July 15, 2023 Category: Consumer Health News Authors: Katie Thomas, Jessica Silver-Greenberg and Robert Gebeloff Tags: Peripheral Vascular Disease Amputation Finances Doctors Medical Devices Surgery and Surgeons your-feed-healthcare Mustapha, Dr. Jihad Saab, Dr. Fadi Abbott Laboratories Blue Cross and Blue Shield of Michigan Boston Scientific Corpora Source Type: news

PAD: The other arterial disease
The body has two types of artery systems: the coronary artery system, which relates to the heart, and peripheral artery system, which involves the arteries carrying oxygenated blood to the arms, legs and brain. Just like coronary arteries, peripheral arteries can become diseased. This condition, called peripheral artery disease, or PAD, narrows arteries and reduces blood flow due to a buildup of fatty deposits on the artery walls. This can cause claudication, which is muscle… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - July 5, 2023 Category: Databases & Libraries Source Type: news

Peripheral artery disease risk factors higher in underrepresented groups
African American, Hispanic, and Native American people face a high risk of developing serious PAD, including amputation, in comparison to white adults. (Source: Yale Science and Health News)
Source: Yale Science and Health News - June 30, 2023 Category: Universities & Medical Training Source Type: news

Black Patients Face Greater Risks From Leg Artery Blockages
FRIDAY, June 16, 2023 -- A new study has unearthed significant racial disparities in both treatment and outcomes for peripheral artery disease (PAD). Black patients with this condition, where plaque builds up in the arteries of the legs, were more... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 16, 2023 Category: General Medicine Source Type: news

Marijuana Linked to Higher PAD Risk Marijuana Linked to Higher PAD Risk
A large study found marijuana users had almost four times the risk of peripheral artery disease, but no higher risk of death or coronary intervention.MDedge News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - May 22, 2023 Category: Primary Care Tags: Cardiology News Source Type: news